Project Grant R01CA293063
Award Date
4/8/25
Completion Date
3/31/30
Dollars Obligated
$654K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This $351,131 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Miami aimed at disrupting the interactions between myeloid-derived suppressor cells (MDSC) and cancer-associated fibroblasts (CAF) in pancreatic cancer. The overarching goals are to: Mechanistically dissect the signaling and spatial interactions between MDSC-derived transmembrane TNF and TNFR2-expressing inflammatory CAFs that govern...
The National Cancer Institute (NCI) has awarded a 5-year, $431,561 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Johns Hopkins University to elucidate the role of the HMGA1 chromatin regulator in pancreatic cancer progression and develop novel therapeutic strategies targeting HMGA1 pathways. The research aims to precisely define HMGA1-dependent mechanisms driving tumor progression and the tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC) using mouse models and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides approximately $578,998 to the University of Nebraska Medical Center to conduct research on targeted therapeutic strategies against pancreatic ductal adenocarcinoma (PDAC), a highly lethal form of pancreatic cancer. The key objectives of this 5-year project are to: 1) determine the mechanisms by which the cancer-specific Tn antigen enhances PDAC tumor progression and identify...
This federal Project Grant award for $648,846.00, provided by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), supports research to investigate the role of stromal senescence in driving tumor progression and altering the tumor immune environment in pancreatic ductal adenocarcinoma (PDAC). The primary awardee, The Washington University in St. Louis, will lead the research with a sub-award to the University of Minnesota to focus on specific aims. The...
This Project Grant award of $636,046 from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) supports research to define the oncogenic potential and therapeutic dependencies of specific KRAS gene variants associated with pancreatic ductal adenocarcinoma (PDAC). The research aims to: Decipher how cell lineage impacts the neoplastic transformation and molecular evolution of epithelial cells in KRAS G12R and G12V mutant PDAC. Define the oncogenic factors...
The National Cancer Institute has awarded a $485,558 Project Grant under the Cancer Biology Research Program (CFDA 93.396) to The General Hospital Corporation (Massachusetts General Hospital) for a 5-year research project focused on characterizing a novel glutathione-related metabolic pathway that drives metastatic growth in pancreatic cancer. The research aims to molecularly define key factors in this pathway, including the enzymes GSTT1 and the amino acid transporter SLC38A4, which are...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Biology Research (CFDA 93.396) program, provides $667,118 to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at identifying and disabling new pathways for macromolecular recycling in pancreatic cancer. The research team will explore the roles of two key lysosomal hydrolases, PLBD1 and LGMN, in supporting pancreatic cancer growth and metastasis, as well as...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) aims to advance the targeted delivery of stromal-targeting therapies for pancreatic ductal adenocarcinoma (PDAC). The $599,474 award, effective September 1, 2024 through August 31, 2029, will support the development of a local controlled-release platform for intratumoral delivery of hyaluronidase. This approach is intended to reduce the dense tumor desmoplasia that acts as a physical...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) will provide $2,675,483 to President and Fellows of Harvard College (Harvard Medical School) to conduct research aimed at understanding the origins and characteristics of peritoneal metastases in colorectal cancer. The 5-year project will leverage a large cohort of 103 peritoneal metastasis patients to map the seeding routes and genetic features of these metastases, as well as examine how...
This $523,480 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the Dana-Farber Cancer Institute, Inc. (DFCI) to study mechanisms of resistance to KRAS inhibitor therapy in pancreatic ductal adenocarcinoma (PDAC). The research aims to define how dysregulated iron metabolism and autophagy pathways contribute to adaptive and acquired resistance to KRAS inhibitors, as well as explore targeting iron overload-induced ferroptosis as a...